Roivant Sciences Reports Q4 2025 Earnings and Key Clinical Updates
Roivant (ROIV) reported $4.3 billion in cash reserves as of March 31, with an additional $950 million expected from a Moderna settlement by July. The company shared positive RA study results for IMVT-1402 showing high response rates and favorable safety data.
Tickers: $ROIV
Topics: brepocitinib fda breakthrough designation mosliciguat ra study results